Race Oncology (ASX:RAC) share price edges higher amid patent update

Race shares have moved into the green after a rollercoaster day so far…

| More on:
Three healthcare workers look and point at at medical image

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Race Oncology Ltd (ASX: RAC) share price has been seesawing today and is now at $3.17. That's a 0.32% gain on the previous closing price.

Race shares have been as high as $3.19 and as low as $3.08 so far today. This comes after an announcement from the company regarding another patent for its Zantrene label.

Here are the details.

Sixth US patent for drug candidate Zantrene

The release notes the US Patent and Trademarks Office (USPTO) issued a new patent on Race's cancer drug candidate, Zantrene.

Zantrene works by inhibiting a particular kind of cancer growth accelerant in the body, known as the fat mass and obesity-associated protein (FTO).

Race is investigating its use in a number of complex conditions as both a substitute and complementary therapy.

As it relates to investors, the company is "pursuing outsized commercial returns for shareholders via its 'three pillar' strategy" to clinically develop Zantrene.

Race was awarded today's patent for "protection around uses of Zantrene that improve the efficacy of Zantrene treatments".

According to the company, the new patent is another plus in Zantrene's launch curve, as it further expands the therapeutic utility of the compound.

It also protects Race's ability to innovate around the flagship drug, particularly to improve patient outcomes. However, today's news has done little to spark the Race Oncology share price.

This marks the sixth granted patent of the phase 2/3 cancer drug candidate, after a recent update earlier this month regarding the fifth patent.

The precision oncology company reckons the USPTO granting a sixth patent only serves to strengthen its growing IP position for Zantrene.

Race Oncology share price snapshot

The Race Oncology share price has boasted an outsized return profile this year to date, having climbed around 80% into the green since January 1.

It has also gained around 230% in the past 12 months. That's well ahead of the benchmark S&P/ASX 200 index (ASX: XJO)'s return of around 19% over the same time.

At the time of writing, Race Oncology has a market capitalisation of $463 million.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

What does the Macquarie Hospital Claims Index mean for ASX 200 health insurance stocks?

Macquarie shares its view on Medibank Private and NIB Holdings.

Read more »

Two lab workers fist pump each other.
Broker Notes

What's JP Morgan's price target on CSL shares?

Are CSL shares undervalued or will they continue to underperform?

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

2 ASX healthcare stocks making huge moves on big news

These shares are getting investors excited today. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is up 15% on guidance upgrade?

Let's find out what is getting investors excited on Tuesday.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

3 reasons why the Sigma Healthcare share price could be a buy

This business has a very exciting outlook.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »